Treatment of chronic hepatitis C with consensus interferon in relapsers and non-responders to interferon-based therapy

Hepato-Gastroenterology

Volumn 54, Issue 80, 2007, Pages 2368-2372

  Steffen, Martin ^a   Cornberg, M ^b   Buggisch, P ^c  

^a FRANZISKUS HOSPITAL   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Chronic hepatitis C; Consensus interferon; Daily dosing; Hepatitis C virus; Induction dosing; Non responder; Ribavirin

Indexed keywords

ALPHA2B INTERFERON; CONSENSUS INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

CLINICAL EVALUATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; MONOTHERAPY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; RECURRENCE; RIBAVIRIN; TREATMENT FAILURE;

EID: 37749029990     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Fleig WE, Krummenerl P, Lesske J et al: Diagnosis, progression and therapy of hepatitis C virus infection as well viral infection in children and adolescents - results of an evidenced based consensus conference of the German Society for Alimentary Metabolic Disorders and in cooperation with the Hepatitis Competence Network. Z Gastroenterol 2004; 42:703-104.
2. Zeuzem S: Standard treatment of acute and chronic hepatitis C. Z Gastroenterol 2004; 42:714-719.
3. Fried MW, Sniffmann ML, Ready KR, et al: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
4. Hadziyannis SJ, Sette H, Morgan TR, et al: Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
5. Manns MP, McHutchison-JG, Gordon SC, et al: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
6. Shiffmann ML, Di Bisceglie AM, Lindsay KL, et al: Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004; 126:1015-1023.
7. Poynard T, Schiff ER, Terg R et al: Sustained virological response (SVR) in the EPIC3 trial: Week 12 virology predicts SVR in previous interferon/ribavirin treatment failures receiving PEG-Intron/Rebetol (PR) weight based dosing (WBD). J Hepatol 2005; 42 (Suppl. 2): 40-41.
8. Marcellin P, Jensen D: Retreatment with PEGASYS® in patients not responding to prior peginterferon alfa-2b/ribavirin (RBV) combination therapy - efficacy analysis of the 12-week induction period of the repeat study. Hepatology 2005; 42(4, Suppl 1):77.
9. Curry M, Cardenas A, Afdhal NH: Effect of maintenance PEG-Intron therapy on portal hypertension and its complications: Results from the COPILOT study. J Hepatol 2005; 42(Suppl 2):40.
10. Pestka S: Human interferon-alpha species and hybrid proteins. Semin Oncol 1997; 24(3, Suppl 9):S9-4-S9-17.
11. Blatt LM, Davis JM, Klein SB, Taylor MW: The biologic activity and molecular characterisation of a novel synthetic interferon-alpha species, consensus interferon. Interferon and Cytokine Res 1996; 16:489-499.
12. Ozes ON, Reiter Z, Klein S, Blatt LM, Taylor MW: A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities. J Interferon Res 1992; 12:55-59.
13. Tong MJ, Blatt LM, Resser KJ, et al: Treatment of chronic hepatitis C virus infection with recombinant consensus interferon. Interferon and Cytokine Res 1998; 18:81-86.
14. Kao JH Chren PJ, Lai MY, Chen DS: Efficacy of consensus interferon in the treatment of chronic hepatitis C. J Gastroenterol Hepatol 2000; 15:1418-1423.
15. Hwang SJ, Lee SD, Chan CY, Lu RH, Chang FY: A randomized, double-blind, controlled trial of consensus interferon in the treatment of Chinese patients with chronic hepatitis C Am F Gastroenterol 1999; 94:2496-2500.
16. Yao GB, Fu XX, Tian GS et al: A multicenter, randomized, controlled trial of interferon alfacon-1 compared with alpha-2a-interferon in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2000; 15:1165-1170.
17. Suzuki H, Sato K, Takagi H, et al: Randomized controlled trial of consensus interferon with or without zinc for chronic hepatitis C patients with genotype 2. World J Gastroenterol 2006; 12:945-950.
18. Tong MJ, Reddy KR, Lee WM, et al: Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial. Hepatology 1997; 26:747-754.
19. Rustgi VK, Bonkovsky HL, Arora S, Zeuzem SP, Manns M, Blatt LM: Daily versus three-times-weekly IFN alfacon-1 in previously untreated HCV patients results in a significant greater rate of SVR: Final results of an international phase 4 study. Gastroenterology 2005; 128(Suppl 2):A-716.
20. Sjogren MH, Sjogren R, Holtzmuller K, et al: Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C. Dig Dis Sci 2005; 50:727-732.
21. Sjogren M, Sjogren R, Lyons MF, et al: Sustained virologic response rates from a randomized trial of HCV genotyp-1 subjects treated with either consensus IFN and ribavirin or pegylated interferon alfa-2b and ribavirin. Hepatology 2005; 42(4 Suppl 1):529A-530A.
22. Miglioresi L, Bacosi M, Russo F, et al: Consensus interferon versus interferon-alpha 2b plus ribavirin in patients with relapsing HCV infection. Hepatol Res 2003; 27:253-259.
23. Heathcote EJL, Keeffe EB, Lee SS, et al: Re-treatment of chronic hepatitis C with consensus interferon. Hepatol 1998; 27:1136-1143.
24. Moskovitz DN, Manoharan P, Heathcote EJ: High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C. Can J Gastroenterol 2003; 17:479-482.
25. Da Silva LA, Bassit L, Ona-Nirta SK, et al: High rate of sustained response to consensus interferon plus ribavirin in chronic hepatitis C patients resistant to alpha-interferon and ribavirin: a pilot study. J Gastroenterol 2002; 37:732-736.
26. Böcher WO, Schumann M, Link R, et al: Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy. Liver International 2006; 26:319-325.
27. Buggisch P, Seegers B, Hinrichsen H, et al: Combination treatment with consensus-Interferon and ribavirin for chronic hepatitis C patients with non-response/relapse to previous treatment with alpha-Interferon and ribavirin. Hepatology 2002; 36(4, Pt. 2):363A.
28. Rothstein, KD, Koka R, Hargrove H: High dose consensus interferon and ribavirin therapy is an effective treatment of chronic hepatitis C infection in patients who are resistant to PEG-interferon and ribavirin - preliminary SVR data. Hapatol 2005; 42:703A.
29. Dollinger MM, Drid Y, Lesske J, et al: Efficacy of daily consensus interferon and ribavirin compared to PEG-interferon alpha-2B and ribavirin in nonresponders with chronic hepatitis C. Hepatol 2005; 42:691A.
30. Chen K, Seraphin P, Murphy L, Shah N: Consensus interferon and ribavirin in patients with chronic hapatitis C who were nonresponders to prior therapy with eiher interferon alfa and ribavirin or pegylated interferon and ribavirin. Hepatol 2005; 42:670A.
31. Cornberg M, Hadem J, Herrmann E, et al: Treatment with daily consensus interferon plus ribavirin in non-responder patients with chronic hepatitis C: A pilot study. J Hepatol 2006; 44:291-301.
32. Kaiser S, Hass HG, Gregor M: Successful retreatment of interferon/ribavirin nonresponders with daily dosing of consensus interferon. J Hepatol 2005; 42(Suppl 2):207-208.
33. Krawitt EL, Ashikaga T, Gordon SC, Ferrentino N, Ray MA, Lidofsky SD: Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. J Hepatol 2005; 43:243-249.
34. Neumann AU, Lam NP, Dahari H, et al: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998; 282:103-107.
35. Zeuzem S, Lee JH, Franke A, et al: Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998; 27:1149-1156.
36. Neumann AU Reddy R, Levi-Drummer R, Poulakos J, Layden TK: Dose-dependent effictiveness of consensus interferon alfacon-1 (Infergen) in blocking in-vivo HCV production. Hepatology 2000; 32(4 Pt 2):372A.
37. Neumann AU Layden TK, Reddy R, Levi-Drummer R, Poulakos J: The 2nd phase slope of HCV decline is highly predictive of sustained virologic response (SVR) following consensus interferon (Infergen) treatment for chronic hepatitis C and is determined by genotype but not by dose. Hepatology 2000; 32(4Pt 2):356A.
38. Layden TJ, Layden JE, Reddy KR, Levy-Drummer RS, Poulakos J, Neumann AU: Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatits C. J Viral Hepat 2002; 9:334-339.
39. Cotler SJ, Layden JE, Neumann AU, Jensen DM: First phase hepatitis C viral kinetics in previous nonresponders patients. J Viral Hepat 2003; 10:43-49.
40. Carithers RL, Zeuzem S, Manns MP, et al: Multicenter, randomized, controlled trail comparing high dose daily induction interferon plus ribavirin versus standard interferon alfa-2b ribavirin. Hepatology 2000; 32(4, Pt2):317A.
41. Fried MW, Shiffmann M, Sterling RK, et al: A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: pretreatment stratification by viral burden and genotype. Am J Gastroenterol 2000; 95:3225-3229.
42. Hadziyannis AS, Papaioannou C, Spanou F, Manesis EK, Hadziyannis SJ: Induction interferon therapy in naove patients with chronic hepatitis C: increased end-of-treatment virological responses but absence of long-term benefit. Aliment Pharmacol Ther 2001; 15: 551-557.
43. McHutchison JG, Manns M, Patel K, et al: Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069.
44. Kaiser S, Hass H, Gregor M: Consensus interferon in combination with gamma-interferon and/or ribavirin leads to a significant response in treatment-naove hepatitis C genotype 1 patients. Hepatology 2005; 42(Suppl 1):277A.
45. Cornberg M, Manns MP: New approaches and therapeutic modalities for the treatment of patients with chronic hepatitis C. Ann Hepatol 2005; 4:144-150.
46. Manns MP, Berg T, Wedemeyer H, et al: Immunization with the therapeutic hepatitis C virus (HCV) peptide vaccine IC41 in 66 chronic hepatitis C nonresponder patients. Hepatology 2004; 40:251A.
47. Nevens F, Roskams T, Van Vlierberghe H, et al: Horsinans Y, Sprengers D, Elewaut A, Desmet V, Leroux-Roels G, de Brauwer A, Depla E, Dincq S, Vander Stichele C, Hulstaert F, Maertens G: Improvement in liver histology after 3 years of El therapeutic vaccination in 23 patients with chronic hepatitis C. Hepatology 2004; 40:250A-251A.
48. Torresi J, Grollo L, Stock O, et al: Cross-Reactive epitopes identified in hepatitis C virus E1E2 protein induce antibodies that capture virions from infected patients' sera and inhibit HCV/HIV pseudo virus entry into susceptible cells. Hepatology 2005; 42(4 Suppl 1):276A.
49. Zeuzem S, Sarrazin C, Wagner F, et al: Combination therapy with the HCV protease inhibitors, SCH 503034, plus PEG-Intron in hepatitis C genotype-1 PEG-Intron non-responders: Phase 1B results. Hepatology 2005; 42(4, Suppl 1):276A-277A.